10-Q: McKesson Reports Strong Q3 Growth, Strategic Acquisitions

McKesson Corporation announced significant revenue and profit increases for the third quarter and first nine months of fiscal 2026, driven by strategic acquisitions and market growth.

Summary

• Revenues for the three months ended December 31, 2025, increased by 11% to $106.16 billion, up from $95.29 billion in the prior year.
• Revenues for the nine months ended December 31, 2025, increased by 15% to $307.14 billion, up from $268.23 billion in the prior year.
• Net income attributable to McKesson Corporation rose 35% to $1.19 billion for the three months, and 51% to $3.08 billion for the nine months.
• Diluted earnings per common share increased 38% to $9.59 for the three months and 57% to $24.73 for the nine months.
• Completed the acquisition of an 80% controlling interest in PRISM Vision Holdings, LLC for $875 million in cash on April 1, 2025.
• Completed the acquisition of a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for $2.5 billion in cash on June 2, 2025.
• Entered into a definitive agreement to sell its retail and distribution businesses in Norway, with the sale completed on January 30, 2026.
• Accrued $17 million in excise taxes for share repurchases during the nine months ended December 31, 2025.
• Returned $2.4 billion to shareholders through $2.1 billion in common stock repurchases and $280 million in dividend payments during the nine months.
• The Board of Directors raised the quarterly dividend to $0.82 per common share from $0.71 on July 29, 2025.
• Restructuring, impairment, and related charges, net were $36 million for the three months and $146 million for the nine months ended December 31, 2025, as part of enterprise-wide initiatives expected to total $650 million to $700 million by fiscal 2028.
• Recorded an immaterial net charge of $29 million related to the bankruptcy of customer Rite Aid Corporation during the nine months ended December 31, 2025.
• Total litigation liabilities for opioid-related claims were $5.71 billion as of December 31, 2025, with $497 million in payments made during the nine months.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, reflecting robust financial performance driven by strategic acquisitions and effective capital allocation. While litigation liabilities and restructuring charges are present, the significant growth in revenue, net income, and EPS, coupled with increased dividends and share repurchases, indicates a positive trajectory.

Positives

• Consolidated revenues increased by 11% for the three months and 15% for the nine months ended December 31, 2025, driven by market growth in North American Pharmaceutical and higher specialty pharmaceutical sales in Oncology & Multispecialty.
• Gross profit increased by 12% for the three months and 8% for the nine months, primarily due to growth in Oncology & Multispecialty and Prescription Technology Solutions.
• Net income attributable to McKesson Corporation increased significantly by 35% for the three months and 51% for the nine months.
• Diluted earnings per common share attributable to McKesson Corporation grew by 38% for the three months ($9.59 vs. $6.95) and 57% for the nine months ($24.73 vs. $15.80).
• Successful strategic acquisitions of PRISM Vision Holdings, LLC ($875 million) and Core Ventures ($2.5 billion) are expected to drive future growth in the Oncology & Multispecialty segment.
• The Board of Directors increased the quarterly dividend to $0.82 per common share, demonstrating confidence in financial performance and commitment to shareholder returns.
• Returned $2.4 billion to shareholders through share repurchases ($2.1 billion) and dividends ($280 million) during the nine months, reducing weighted-average diluted common shares outstanding.
• Operating income increased by 33% for the three months and 43% for the nine months, reflecting improved operational efficiency.
• The reported income tax rate decreased to 20.4% for the nine months ended December 31, 2025, from 23.5% in the prior year, partly due to a $119 million discrete tax benefit from the release of a valuation allowance in a foreign jurisdiction.

Negatives

• Restructuring, impairment, and related charges, net were $36 million for the three months and $146 million for the nine months ended December 31, 2025, indicating ongoing costs associated with operational efficiency initiatives.
• An immaterial net charge of $29 million was recorded for the nine months ended December 31, 2025, related to the bankruptcy of customer Rite Aid Corporation, impacting selling, distribution, general, and administrative expenses.
• Cash and cash equivalents decreased from $5.69 billion at March 31, 2025, to $2.96 billion at December 31, 2025, primarily due to significant acquisition payments.
• Working capital decreased from $(6.21) billion at March 31, 2025, to $(8.43) billion at December 31, 2025, mainly due to increased drafts and accounts payable and decreased cash.
• Net cash used in investing activities increased significantly to $3.86 billion for the nine months ended December 31, 2025, from $509 million in the prior year, largely due to acquisitions.
• Net cash used in financing activities increased to $1.81 billion for the nine months ended December 31, 2025, from $1.11 billion in the prior year, despite lower share repurchases, due to higher debt repayments.

Risks

• Ongoing opioid-related litigation matters pose a significant financial risk, with total litigation liabilities of $5.71 billion as of December 31, 2025, and potential for substantial future payments or adverse judgments.
• The company is subject to a variety of claims and legal proceedings, including governmental investigations, which could result in substantial payments, injunctions, or forced changes in business operations.
• Changes in regulatory policies and government funding of healthcare costs could materially adversely impact operations, with ultimate outcomes difficult to predict.
• Goodwill impairment risks exist, as future developments such as government actions, increased regulatory uncertainty, and material changes in key market assumptions could adversely affect the fair value of reporting units.
• Fluctuations in foreign currency exchange rates and interest rates expose the company to financial risks, although hedging activities are in place to mitigate these.
• The company's ability to meet its debt covenants in the future could be impacted by unforeseen circumstances, potentially leading to suspension of credit facility use or required repayment of outstanding balances.
• The ongoing enterprise-wide restructuring initiatives, while intended to improve efficiency, involve significant anticipated charges of $650 million to $700 million through fiscal 2028, which could impact financial performance.

Future Outlook

The company anticipates continuing to pay quarterly cash dividends in the future, subject to Board discretion and financial performance. Enterprise-wide initiatives to modernize technology and streamline the organization are expected to incur total charges of $650 million to $700 million, primarily for employee severance and facility costs, and are anticipated to be substantially complete in fiscal 2028. The company expects its available cash, short-term investments, and credit facilities to be sufficient to fund short-term and long-term capital expenditures, working capital, and other cash requirements.

Management Comments

• NA

Industry Context

StockSavvy.ai notes that McKesson's strong revenue growth, particularly in North American Pharmaceutical and Oncology & Multispecialty, aligns with broader trends of increasing drug utilization and the growing demand for specialty pharmaceuticals and integrated healthcare solutions. The strategic acquisitions of PRISM Vision and Core Ventures demonstrate a clear focus on expanding high-growth, value-added services within the oncology and multispecialty sectors, positioning the company to capitalize on the shift towards more complex and specialized care. The planned separation of the Medical-Surgical Solutions segment suggests a strategic move to streamline operations and potentially unlock value by allowing each entity to focus on its core business and market opportunities. The ongoing opioid litigation remains a significant industry-wide challenge, but McKesson's established settlement framework provides some clarity on future liabilities.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in numerous opioid-related lawsuits filed by state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals in the U.S., Puerto Rico, and Canada.
• Under a settlement agreement with 48 states and participating subdivisions, the company has paid approximately $2.5 billion as of December 31, 2025, and will pay up to approximately $5.4 billion through 2038.
• A separate settlement agreement with Alabama and its subdivisions involves payments of approximately $89 million as of December 31, 2025, and an additional $85 million through 2031.
• Settlement with certain West Virginia subdivisions involves payments of approximately $68 million as of December 31, 2025, with an additional $15 million paid in January 2026 and $69 million through 2033.
• The U.S. Court of Appeals for the Fourth Circuit reversed a trial court decision in favor of the company regarding claims by Cabell County and the City of Huntington, remanding the case for additional proceedings.
• A jury in the City of Baltimore case found the company liable for approximately $192 million in compensatory damages, later reduced to $37 million by the court, with an additional $72 million ordered for monetary abatement; the company has appealed these judgments.
• The company reached class-action settlements with nationwide groups of acute care hospitals ($149 million charge) and certain third-party payors ($114 million charge) for opioid-related claims.
• Total estimated accrued liability for opioid-related claims of U.S. governmental entities, Native American tribes, and certain non-governmental plaintiffs was $5.71 billion as of December 31, 2025.
• Four opioid-related cases are pending in Canada, involving provincial governments, municipal governments, indigenous people, and an individual, with a common-issues trial scheduled for February 22, 2028.
• Received net proceeds of $15 million related to its share of antitrust settlements from lawsuits against drug manufacturers, recognized as a gain in 'Cost of sales'.
• Received a $28 million recovery from the State of New York to settle a lawsuit challenging the constitutionality of the New York Opioid Stewardship Act.

Related Party Transactions

• Noncontrolling interests with redemption features (redeemable noncontrolling interests) were initially recognized at $25 million for PRISM Vision and $700 million for Core Ventures, with adjustments to redemption value recorded quarterly.
• Net income attributable to noncontrolling interests includes third-party equity interests in ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC.

Stakeholder Impact

• Shareholders: Benefited from a 38% increase in diluted EPS for the three months and 57% for the nine months, a raised quarterly dividend to $0.82 per share, and $2.1 billion in share repurchases, indicating strong returns and capital management.
• Employees: Impacted by restructuring initiatives, which include employee severance and other employee-related costs, as the company aims to streamline the organization.
• Customers (Rite Aid): The company recorded an immaterial net charge of $29 million due to the bankruptcy of Rite Aid Corporation, reflecting potential impacts on customer relationships and receivables.
• Governmental Entities and Native American Tribes: Received significant settlement payments for opioid-related claims, with ongoing payments expected through 2038, contributing to remediation efforts for the opioid epidemic.
• Creditors: The company issued $2.0 billion in new public debt to fund acquisitions, increasing long-term debt, but remains in compliance with all debt covenants, maintaining access to capital markets.

Next Steps

• Completion of enterprise-wide initiatives to modernize technology and streamline the organization, anticipated to be substantially complete in fiscal 2028.
• Continued payment of quarterly cash dividends, subject to Board discretion.
• Ongoing defense against opioid-related litigation matters not covered by settlement agreements.
• Monitoring of the appeal process for the City of Baltimore opioid litigation judgment.
• Evaluation of the financial impact of the completed sale of the Norway disposal group.
• Potential conversion of outstanding loans under the 364-Day Credit Facility into a term loan repayable in May 2027.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with double-digit revenue growth, substantial increases in net income and diluted EPS, and a strong commitment to shareholder returns through increased dividends and significant share repurchases. Strategic acquisitions in high-growth areas like oncology and multispecialty are expected to drive future expansion. While ongoing opioid litigation and restructuring charges present some headwinds, the company's robust operational results, effective capital allocation, and positive outlook suggest a compelling investment opportunity for long-term growth.

Keywords

Healthcare Services, Pharmaceutical Distribution, Oncology, Specialty Pharmaceuticals, Prescription Technology Solutions, Medical-Surgical Solutions, SEC Filing, 10-Q, Earnings Report, Acquisitions, Divestitures, Opioid Litigation, Share Repurchase, Dividends, Restructuring, Financial Performance